4 terminated, 1 completed, 1 withdrawn. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 4, Completed 1, Withdrawn 1 |
Follow Ikena Oncology: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors IK-595 - Solid Tumor, Adult, Colorectal Cancer | Phase 1 | Terminated | Ikena Oncology | 75 | 2023-12-18 | 2025-09-19 |
| Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer IK-175 + nivolumab - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 1 | Withdrawn | Ikena Oncology | 2023-03-01 | 2024-03-15 | |
| Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors IK-930, Osimertinib - Solid Tumors, Adult, Solid Tumor | Phase 1 | Terminated | Ikena Oncology | 67 | 2022-01-07 | 2024-11-18 |
| A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3 - Advanced Solid Tumor, Gynecologic Cancer | Phase 1 | Terminated | Ikena Oncology | 127 | 2020-11-10 | 2024-03-22 |
| A Study of PY314 in Subjects With Advanced Solid Tumors PY314, Combination Therapy: PY314 + Pembrolizumab - Advanced Solid Tumor, Gynecologic Cancer | Phase 1 | Terminated | Ikena Oncology | 86 | 2020-10-29 | 2024-03-22 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma IK-175, IK-175 and nivolumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 1 | Completed | Ikena Oncology | 78 | 2019-12-18 | 2024-03-15 |
Colorectal Neoplasms (3) · Adenocarcinoma of Lung (2) · Breast Neoplasms (2) · Head and Neck Neoplasms (2) · Pancreatic Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Glioma (1) · Hemangioendothelioma, Epithelioid (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Nivolumab (2) · pembrolizumab (2) · osimertinib (1)
United States (6) · Australia (1) · United Kingdom (1)
Caroline Germa, MD (2) · Karim Malek, MD (2) · Katherine Kim, MD (2) · Len Reyno, MD (2) · Marc Chamberlain, MD (2)